BlackRock Amends Passive Stake in Acadia Pharmaceuticals
Ticker: ACAD · Form: SC 13G/A · Filed: Jan 26, 2024 · CIK: 1070494
| Field | Detail |
|---|---|
| Company | Acadia Pharmaceuticals Inc (ACAD) |
| Form Type | SC 13G/A |
| Filed Date | Jan 26, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**BlackRock still holds ACADIA PHARMACEUTICALS stock, signaling institutional confidence.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 26, 2024, indicating its ownership of ACADIA PHARMACEUTICALS INC common stock as of December 31, 2023. This filing is an amendment (Amendment No: 2) to a previous filing, showing BlackRock's continued significant, but passive, stake in Acadia Pharmaceuticals. For investors, this matters because BlackRock is a major institutional investor, and its continued holding signals a degree of confidence in the company's long-term prospects, even if the exact percentage of ownership isn't detailed in this snippet.
Why It Matters
BlackRock's continued passive ownership in ACADIA PHARMACEUTICALS INC suggests institutional confidence, which can be a positive signal for current and prospective shareholders.
Risk Assessment
Risk Level: low — This filing is a routine update from a large institutional investor and does not indicate any immediate significant risk or change in company operations.
Analyst Insight
An investor should view this as a routine update from a major institutional holder, suggesting stability rather than an immediate catalyst for buying or selling. Further research into Acadia's fundamentals and BlackRock's overall investment strategy would be prudent.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- ACADIA PHARMACEUTICALS INC (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 26, 2024 (date) — the filing date of the SC 13G/A amendment
- 004225108 (other) — the CUSIP number for ACADIA PHARMACEUTICALS INC Common Stock
Forward-Looking Statements
- BlackRock will maintain a significant, passive stake in ACADIA PHARMACEUTICALS INC. (BlackRock Inc.) — high confidence, target: Q4 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment (Amendment No: 2) to a Schedule 13G filing under the Securities Exchange Act of 1934.
Who is the reporting person in this filing?
The reporting person is BlackRock, Inc., a large institutional investment manager.
What company's securities are being reported on in this filing?
The securities being reported on belong to ACADIA PHARMACEUTICALS INC, specifically their Common Stock.
What was the 'Date of Event Which Requires Filing of this Statement'?
The date of the event which requires filing of this statement was December 31, 2023.
Under which rule is this Schedule 13G/A filed?
This Schedule 13G/A is filed under Rule 13d-1(b) of the Securities Exchange Act of 1934, as indicated by the 'X' in the appropriate box.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 26, 2024 regarding ACADIA PHARMACEUTICALS INC (ACAD).